Danaher Corporation Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Life Sciences Tools and Services | Market Cap: ₹1.3L Cr
- Full-year 2026 core revenue growth guidance remains at 3% to 6%, with low single-digit growth expected in Q2 and acceleration through the year. - Danaher expects mid- to high single-digit earnings growth in H1 2026, putting them on track for the full year.
From Danaher Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹180.63
Market Cap
₹1.3L Cr
P/E Ratio
33.5
Revenue Rank
Margin Rank
How does Danaher Corporation rank in Life Sciences Tools and Services?
Compare Danaher Corporation against every Life Sciences Tools and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →Full-year 2026 core revenue growth guidance remains at 3% to 6%, with low single-digit growth expected in Q2 and acceleration through the year.
- →Headwinds from China diagnostics, respiratory, and life sciences comps (~300 basis points) are expected to abate by year-end, enabling mid-single-digit core growth exit in Q4.
- →Encouraged by early 2026 momentum: Life Sciences and Biotechnology businesses in China accelerating; bioprocessing consumables showing consistent high single-digit growth; equipment orders improving with over 30% YoY increase.
- →Equipment orders growth in bioprocessing expected to support growth beyond 2026, though 2026 guide assumes flat equipment revenue.
- →Masimo acquisition expected to be accretive to adjusted diluted net earnings in the first full year post-acquisition and deliver high single-digit return by year five.
- →AI is anticipated to accelerate pharma development, leading to increased demand for Life Science and Bioprocessing solutions.
📈 Profitability & Margins
Rank 3- →Danaher expects mid- to high single-digit earnings growth in H1 2026, putting them on track for the full year. (Page 7)
- →Full-year 2026 adjusted diluted EPS guidance was raised slightly to a range of $8.35 to $8.55, up from $8.35 to $8.50 previously. (Page 4)
- →The company plans for low single-digit core revenue growth in Q2 2026, with a sequential improvement from Q1. (Page 4)
- →Core growth guidance for full-year 2026 remains 3% to 6%. (Page 4)
- →Headwinds impacting growth (~300 basis points) expected to abate by year-end, supporting acceleration to mid-single-digit revenue growth exiting Q4. (Pages 4, 11, 12)
- →High single-digit growth in bioprocessing consumables expected to continue, with equipment growth possibly accelerating beyond flat guidance. (Page 5, 7)
- →The respiratory segment expects a return to an endemic revenue rate (~$1.8 billion) by Q4, benefiting overall results. (Page 12)
🏗️ Capital Expenditure Plans
Yes- →Danaher is accelerating growth investments, moving some from the second half of the year into Q2 to capitalize on opportunities.
- →There is notable investment activity in bioprocessing equipment, supported by more than 30% year-over-year order growth, driven by underinvestment in capacity and new biosimilars and compounds entering the market.
- →Brownfield and greenfield investments are underway, including equipment capacity expansions and reshoring-related projects, with some orders already placed for brownfield expansions.
- →The company is enhancing its portfolio via strategic M&A, highlighted by the pending acquisition of Masimo, expected to close later this year.
- →Investments are also reflected in new product introductions and strategic partnerships, such as Cytiva's advanced mRNA purification platform and Beckman Coulter Life Sciences' partnership with Automata for AI-driven tools.
- →Overall, Danaher emphasizes continual capital deployment backed by strong free cash flow and a robust balance sheet.
💰 Fundraising & Capital Structure
No information- →No explicit mention of new fundraising through debt or equity in the provided transcript.
- →Post-Masimo deal, the company expects a net debt leverage of about 2.5 turns.
- →Strong free cash flow generation of over $5 billion per year and EBITDA support rapid deleveraging.
- →The company feels well-positioned with a strong balance sheet for further capital deployment, including M&A.
- →No indication of plans to raise equity; focus is on using existing balance sheet capacity and cash flow.
- →Overall readiness to pursue acquisitions using current financial resources without needing new fundraising.
📋 Order Book & Pipeline
Yes- →Bioprocessing equipment orders showed over 30% year-over-year growth in Q1, coming off a lower base the previous year.
- →The first quarter orders growth was the first positive year-over-year growth in nearly 2 years.
- →Sequentially, Q1 orders were slightly down quarter-over-quarter due to typical seasonality.
- →Equipment order book trends are supported by robust funnel activity and larger order sizes.
- →Orders growth driven by two factors: underinvestment in capacity (brownfield and greenfield investments) and reshoring dynamics.
- →Equipment orders assumed to be flat for the full year 2026, with positive indicators for future growth beyond 2026.
- →Customer readiness may cause lumpiness in equipment revenue recognition.
- →In Diagnostics, good momentum with solid funnel activity outside China.
- →Life Sciences shows improving funnel activity and stable or improving demand across segments.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Life Sciences Tools and Services this season
- Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
- Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
- Illumina, Inc. (Q2 FY26)
Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma
- Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
Frequently Asked Questions
What were Danaher Corporation Q2 FY26 results?
- Full-year 2026 core revenue growth guidance remains at 3% to 6%, with low single-digit growth expected in Q2 and acceleration through the year. - Danaher expects mid- to high single-digit earnings growth in H1 2026, putting them on track for the full year.
What is Danaher Corporation share price analysis?
Danaher Corporation currently shows a neutral. The stock trades at a P/E of 33.5 with a market cap of $127,845. Investors should review the full earnings analysis for detailed insights.
Is Danaher Corporation planning capital expenditure?
- Danaher is accelerating growth investments, moving some from the second half of the year into Q2 to capitalize on opportunities.
Keep Danaher Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.